Fig. 1: Elevated SNHG3 c.1746 A > I editing is associated with poor NSCLC prognosis.

a Volcano plot identifying lymph node metastasis-associated A-to-I editing events (|r | ≥ 0.05, P < 0.05), with positively and negatively correlated sites shown in red and light green, respectively. b Survival-associated A-to-I editing events (|lnHR | > 0.4, P < 0.005), where red indicates increased mortality risk and green indicates decreased risk. c Venn diagram and table displaying three overlapping A-to-I editing sites that are significantly associated with both metastasis and survival. d Sanger sequencing chromatograms comparing cDNA (top) and genomic DNA (gDNA, bottom), with the arrow indicating the c.1746 A > I editing site. e, f BASEscope in situ hybridization images showing distinct localization of wild-type SNHG3 (SNHG3^WT, green) and edited SNHG3 (SNHG3^ED, red) in cultured cells (e; scale bar = 10 μm) and clinical specimens (f; scale bar = 50 μm). g Quantitative analysis of c.1746 A > I editing levels by pyrosequencing. h Comparison of editing frequencies between matched tumor and adjacent normal tissues (paired t-test). Significant differences in editing levels between patients with and without lymph node metastasis (i) or distant metastasis (j) (unpaired t-test with Welch’s correction). k Kaplan-Meier survival curves demonstrating poorer overall survival in patients with high c.1746 A > I editing (log-rank test). Error bars represent mean ± SD (i, j).